Diagnostic model of esophageal varices in alcoholic liver disease

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 3, 2005, Pages 307-309

  Suzuki, Ayako ^a   Mendes, Flavia ^b   Lindor, Keith ^b  

^a DUKE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Alcoholic liver disease; Esophageal varices; Hyaluronic acid

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; HYALURONIC ACID;

ALCOHOL LIVER DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC MODEL; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; MODEL; NON INVASIVE MEASUREMENT; PORTAL HYPERTENSION; PREDICTION; PRIORITY JOURNAL; REVIEW; SCREENING;

BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYALURONIC ACID; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, ALCOHOLIC;

EID: 15744372794     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200503000-00008     Document Type: Review

References (27)

1. Groszmann RJ, de Franchis R. Portal hypertension. In: Schiff ER, Sorrell MF, Maddrey WC (eds): Schiff's Disease of the Liver. 1999, Philadelphia, New York: Lippincott-Raven; pp. 387-442.
2. Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. W Engl J Med 2001; 345(9):669-681.
3. Grace ND, et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 1998; 28(3):868-880.
4. Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee [see comment]. American Journal of Gastroenterology 1997; 92(7):1081-1091.
5. Regev A, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. American Journal of Gastroenterology 2002; 97(10):2614-2618.
6. Spiegel BM, et al. Endoscopic screening for esophageal varices in cirrhosis: Is it ever cost effective? Hepatology 2003; 37(2):366-377.
7. Arguedas MR, et al. Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices. Am J Gastroenterol 2002; 97(9):2441-2452.
8. D'Amico G, Morabito A. Noninvasive markers of esophageal varices: another round, not the last [comment]. Hepatology 2004; 39(1):30-34.
9. Chalasani N, et al. Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol 1999; 94(11):3285-3291.
10. Madhotra R, et al. Prediction of esophageal varices in patients with cirrhosis [see comment]. Journal of Clinical Gastroenterology 2002; 34(1):81-85.
11. Giannini E, et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003; 52(8):1200-1205.
12. Ng FH, et al. Prediction of oesophagogastric varices in patients with liver cirrhosis. Journal of Gastroenterology & Hepatology 1999; 14(8):785-790.
13. Pilette C, et al. Non-invasive diagnosis of esophageal varices in chronic liver diseases. Journal of Hepatology 1999; 31(5):867-873.
14. Schepis F, et al. Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? [comment]. Hepatology 2001; 33(2):333-338.
15. Thomopoulos KC, et al. Non-invasive predictors of the presence of large oesophageal varices in patients with cirrhosis. Digestive & Liver Disease 2003; 35(7):473-478.
16. Zaman A, et al. Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am J Gastroenterol 1999; 94(11):3292-3596.
17. Zaman A, et al. Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage [see comment]. Archives of Internal Medicine 2001; 161(21):2564-2570.
18. Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis [see comment]. Hepatology 2004; 39(1):204-210.
19. Tamaki S, et al. Evaluation of hyaluronic acid binding ability of hepatic sinusoidal endothelial cells in rats with liver cirrhosis. Gastroenterology 1996; 111(4):1049-1057.
20. Guechot J, Poupon RE, Poupon R. Serum hyaluronan as a marker of liver fibrosis. Journal of Hepatology 1995; 22(Suppl. 2):103-106.
21. Oberti F, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113(5):1609-1616.
22. Plevris JN, et al. Serum hyaluronan - a non-invasive test for diagnosing liver cirrhosis. European Journal of Gastroenterology & Hepatology 2000; 12(10):1121-1127.
23. Engstrom-Laurent A, et al. Increased serum levels of hyaluronate in liver disease. Hepatology 1985; 5(4):638-642.
24. Stickel F, et al. Serum hyaluronate correlates with histological progression in alcoholic liver disease [see comment]. European Journal of Gastroenterology & Hepatology 2003; 15(9):945-950.
25. Pares A, et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996; 24(6):1399-1403.
26. Suziki A et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with nonalcoholic fatty liver disease. Liver International (In Press).
27. Lelbach WK. Leberschaden bei chronischem Alkoholismus. Ergebnisse einer klinischen, klinisch-chemischen und bioptisch-histologischen Untersuchung an 526 Alkoholkranken wahrend der Entziehungskur in einer offenen Trinkerheilstatte. Acta Hepato-Splenotogica, 1967; 14(1):9-39.